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ABSTRACT
Gemtuzumab ozogamicin, an anti-tumour antibiotic linked to an anti-CD33 antibody (Mylotarg®),
has been well studied in AML in adults but to a lesser extent in children. No review has yet been
published on the dose-related toxicity and efficacy of gemtuzumab ozogamicin in pediatric AML
patients. Here we looked at 14 studies then scatterplots and linear regressions were used to
estimate the relationship between the dose of gemtuzumab and its toxicity and efficacy. A non-
significant increase in bilirubin level and in incidence of veno-occlusive disease was seen with
higher doses of gemtuzumab ozogamicin when used as single-agent. In terms of efficacy, even a
low dose of 3 mg/m2 of gemtuzumab ozogamicin can have antileukemic effect, but available
data do not allow conclusions on its dose-dependency. Data indicate that higher doses of
gemtuzumab ozogamicin account for more adverse events. The data do not show that a high
dose is required for anti-leukemic efficacy of gemtuzumab ozogamicin. This study also indicates
that there seems to be a role for gemtuzumab ozogamicin in the treatment of pediatric AML and
further studies are required to assess its optimal dose, schedule and balance between efficacy
and side-effects.
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Introduction
The prognosis of acute myeloid leukemia (AML) in chil-
dren has improved tremendously during the last dec-
ades with current survival rates approximating 70% [1].
Unfortunately, one-third of the patients eventually
relapse [1–8]. Over the past years, new therapies have
been designed to improve the prognosis in AML includ-
ing the development of antigen-targeted therapies.
Gemtuzumab ozogamicin (GO), also known as
Mylotarg® (Wyeth-Ayerst Pharmaceuticals, Radnor, PA,
USA), consists of a humanized monoclonal IgG4 anti-
body (hP67.6) against the CD33 antigen linked to a
derivative of calicheamicin (N-acetyl-γ calicheamicin
1,2-dimethyl hydrazine dichloride), an antitumor anti-
biotic [9]. The CD33 surface antigen is present in
approximately 90% of AML cells [10].
GO was first studied in adults before it was used in
children. The first study in 1999 in 40 adults, a phase I
dose-escalation study, showed that maximum tolerated
dose of GO as a single agent was considered to be
9 mg/m2 and resulted in a reduction in bone marrow
leukemic blast count to <5% in eight patients (20%).
Most reported toxicities were infusion-related chills,
fever and myelosuppression. Dose-limiting toxicity was
defined as severe marrow hypoplasia of ≤6 weeks dura-
tion after a single dose of GO, one grade IV study drug-
related toxic effect or two grade IV toxic conditions of
ambiguous relationship to GO [11].
Based on the results of this study, an open-label
multicenter phase II trial with GO at 9 mg/m2 was
started in ≤200 adults with AML. The overall response
rate was 30%. The most frequent side effect was severe
myelosuppression, and about 30% of the patients
developed grade 3 or 4 treatment-related infections.
Furthermore, some patients developed an increase of
bilirubin (23%) and transaminases (17%). Abnormalities
of liver function were generally transient and reversible.
Veno-occlusive disease (VOD) occurred in seven
patients (3%), of whom two patients deceased [12].
VOD is the most severe adverse event of GO. Because
of the concerns in adults regarding liver toxicity using
higher doses of GO in combination with other cytotoxic
agents, subsequent pediatric and adult trials have
reduced the dose of GO and it was advised to have
an interval between GO and stem cell transplantation of
at least 3.5 months [13]. Larson et al. reported in 2005
that 0.9% of 277 patients in their study developed VOD
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[14].The single-agent use of GO resulted in a 26%
remission rate with no major side effects. McKoy et al.
reported that of adult AML patients who received GO in
clinical trials, in total 3% experienced VOD when given
GO ≤ 6 mg/m2, administered as monotherapy or in
combination with nonhepatotoxic agents. On the
other hand, when GO was combined with thioguanine,
28% experienced VOD [14,15].
GO was approved by the US FDA in 2000 for its use
in patients with relapsed AML being 60 years or older,
but withdrawn in 2010 by Pfizer (previously Wyeth)
because of adverse events and doubts regarding its
effectiveness in a pivotal study in which mortality with
gemtuzumab was 5.7% compared to 1.4% without the
agent [16]. Since then, studies in newly diagnosed AML
in adults have regenerated interest in the compound
[17–20].
In 2011, Burnett et al. reported from the Medical
Research Council AML 15 trial that a significant propor-
tion of younger patients, especially patients with favor-
able cytogenetics, with AML had improved survival rate
with the addition of GO to induction chemotherapy
[17]. Another study from Burnett et al. reported in
2012 shows similar data in another group of patients,
that is, elderly patients with AML. The authors con-
cluded that adding GO at a dose of 3 mg/m2 to induc-
tion chemotherapy reduces relapse risk and improves
chances of survival with little additional toxicity [18].
In 2012, Castaigne et al. reported on a randomized,
open-label, phase 3 study. They investigated whether
the addition of five doses of intravenous GO (3 mg/m2)
to the standard frontline chemotherapy would improve
the outcome of patients with AML without causing
excessive toxicity. After 2 years, significant
improvement was found in relapse-free survival,
event-free survival (EFS) and overall survival.
Hematological toxicity, especially prolonged thrombo-
cytopenia, was significantly more common in the GO
group than in the control group [19].
These studies warrant reassessment of GO as front-
line therapy for AML in adults and suggest the useful-
ness of this drug in pediatric AML as well. Currently, at
least four trials on GO, (also) enrolling children, are still
active (Table 1).
In 2003, the first data on the use of GO in children
were published by Zwaan et al. They treated 15 chil-
dren on a compassionate-use basis with different doses
of GO, ranging from 4 to 9 mg/m2 [21]. Several studies
about the use of GO in children have been reported
since then. {Gamis, 2014 112 /id;de Vries, 2012 18 /id;
Loke, 2015 116 /id} In pediatric trials, different sche-
dules have been used to diminish the risk of complica-
tions, but an optimal dose and schedule has yet to be
established. No review has been published so far on the
dose-related toxicity and efficacy of GO in pediatric
AML. We, therefore, reviewed and compared all eligible
and published studies regarding the use of GO in chil-
dren in relationship to its dose-related toxicity and
efficacy.
Search strategy
We have used PubMed and Embase electronic data-
bases, with no restrictions on date of publication, to
identify studies about the dose-related toxicity and
efficacy of GO in children. The keywords combination
we have applied is shown in Table 2. To broaden our
search strategy, we applied not only GO, but also
Table 1. Overview of ongoing clinical trials of gemtuzumab ozogamicin in AML, also enrolling children.
Title Status
Number of
patients
Dose of GO
(mg/m2)
Combination/
single agent
therapy Trial number
Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With
ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)
Recruiting 100 9 Combination NCT01409161
Allogeneic Stem Cell Transplantation Following by Targeted Immune
Therapy (Gemtuzumab Ozogamicin) in Average Risk Acute
Myelogenous Leukemia and Myelodysplastic Syndrome (AML/MDS)(IND
111024)
Recruiting 26 (up to 30
years)
9 Single agent NCT02117297
Allogeneic Stem Cell Transplantation Followed by Targeted Immune
Therapy In Average Risk Acute Myelogenous Leukemia/Myelodysplastic
Syndrome/Juvenile Myelomonocytic Leukemia (AML/MDS/JMML)
Ongoing,
not
recruiting
18 (1 month till
64 years
Dose-
escalation
regimen
Combination NCT01020539
Gemtuzumab Ozogamicin (Mylotarg [Registered]) Expanded Access
Protocol for Treatment of Patients in the United States with Relapsed/
Refractory Acute Myelogenous Leukemia Who May Benefit from
Treatment and Have No Access to Other Comparable/Alternative
Therapy
Expanded
access
Unknown (3
months and
older)
9 mg/m2 as
a single
agent
Single agent
and
combination
NCT02312037
A Pilot Study of Gemtuzumab Ozogamicin in Combination with Busulfan
and Cyclophosphamide (Bu/Cy) (Immunochemotherapy) and Allogeneic
Stem Cell Transplantation (AlloSCT) in Patients with High Risk Acute
Myelogenous Leukemia and Myelodysplastic Syndrome (AML/MDS)
Recruiting 25 (up to
30 years old
7.5 Combination NCT02221310
AML: acute myeloid leukemia; GO: gemtuzumab ozogamicin.
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Mylotarg. No limits were used to broaden our search
strategy. All articles until 24 February 2015 were
included in the search. Also, bibliographies of the
obtained articles were screened for relevant publica-
tions. In total, 442 abstracts from two databases were
screened, 87 from PubMed and 355 from Embase.
Twenty-seven articles were included based on their
abstracts. After reading full-text articles, 14 studies
were included in this study [4,21–33].
Selection criteria
Studies were first selected based on their title. After
initial selection, inclusion criteria were children from 0
to 18 years old and studies about the use of GO in AML.
Exclusion criteria were no separate data on GO, no
separate data on children, case reports, no English
full-text available, studies on other diseases than AML,
and no toxicity or efficacy data available. Figure 1
shows the selection process. In total, 340 articles were
excluded based on title or abstract; 29 articles were
excluded because of lack of clinical data, 21 articles
showed no separate data on children, 3 articles were
not published in English, 214 articles had no separate
data on GO, 15 articles contained only data about VOD,
52 articles were about other diseases than AML and 6
studies had no efficacy data.
Statistical analysis and definitions
All extracted data were analyzed with SPSS Statistics 20
[34]. Complete remission (CR) was defined as bone
marrow blasts <5%, absence of blasts with Auer rods,
absence of extramedullary disease, absolute neutrophil
count ≤1.0 × 109/L (1000/µL), platelet count ≤100 ×
109/L (100,000/µL) and independence of red cell trans-
fusions. CR with incomplete blood count recovery (CRi)
was defined as all CR criteria except for residual neu-
tropenia (<1.0 × 109/L (1000/µL)) and/or thrombocyto-
penia (<100 × 109/L (100,000/µL))[35].
Hyperbilirubinemia was graded according to the
grading system of the NCI, the Common Toxicity
Criteria for Adverse Events, version 4.0: CTCAEv4. VOD
was classified according to the Seattle criteria [36,37].
From previous studies, it is known that VOD is the most
severe side effect of GO. Therefore, a special focus was
given to VOD as toxicity. To determine which variables
are likely to be confounders or effect modifiers of the
incidence of VOD, we carried out univariate linear regres-
sion analyses to determine which variables were most
significantly associated with toxicity of GO. First of all, we
Table 2. Search terms electronic databases.
Database 30
February 2015 Search terms
PubMed ‘Child’[Mesh] OR ‘Infant’[Mesh] OR child*[tw] OR
schoolchild*[tw] OR infan*[tw] OR adolescen*[tw]
OR pediatri*[tw] OR paediatr*[tw] OR neonat*[tw]
OR boy[tw] OR boys[tw] OR boyhood[tw] OR girl
[tw] OR girls[tw] OR girlhood[tw] OR youth[tw] OR
youths[tw] OR baby[tw] OR babies[tw] OR toddler*
[tw] OR teen[tw] OR teens[tw] OR teenager*[tw] OR
newborn*[tw] OR postneonat*[tw] OR postnat*[tw]
OR puberty[tw] OR preschool*[tw] OR suckling*[tw]
OR picu[tw] OR nicu[tw] OR ‘Leukemia,
Myelomonocytic, Juvenile’[Mesh] AND
‘gemtuzumab’ [Supplementary Concept] OR
gemtuzumab[tiab] OR Mylotarg[tiab]
Embase [embryo]/lim OR [fetus]/lim OR [newborn]/lim OR
[infant]/lim OR [preschool]/lim OR [school]/lim OR
[child]/lim OR [adolescent]/lim OR child*:ab,ti OR
schoolchild*:ab,ti OR infan*:ab,ti OR adolescen*:ab,
ti OR pediatri*:ab,ti OR paediatr*:ab,ti OR neonat*:
ab,ti OR boy:ab,ti OR boys:ab,ti OR boyhood:ab,ti
OR girl:ab,ti OR girls:ab,ti OR girlhood:ab,ti OR
youth:ab,ti OR youths:ab,ti OR baby:ab,ti OR babies:
ab,ti OR toddler*:ab,ti OR teen:ab,ti OR teens:ab,ti
OR teenager*:ab,ti OR newborn*:ab,ti OR
postneonat*:ab,ti OR postnat*:ab,ti OR puberty:ab,ti
OR preschool*:ab,ti OR suckling*:ab,ti OR picu:ab,ti
OR nicu:ab,ti OR ‘childhood leukemia’/exp AND
‘gemtuzumab ozogamicin’/exp OR gemtuzumab:ab,
ti OR mylotarg:ab,ti
Titles reviewed: total = 442
Pubmed = 87
Embase = 355
27 full-text articles requested
14 articles included for review 
and analysis
Excluded: Total =  13
No separate analysis of 
children’s data =  7
No data of  efficacy =  1
No full-text available = 4
Case report = 1
75 duplicated records removed
340 articles excluded based on 
title and abstract
Figure 1. Overview selection criteria for study inclusion.
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determined with Spearman’s rho whether the total sin-
gle and cumulative dose of GO had a causal relationship
with the incidence of VOD and bilirubin elevation.
Scatterplots were used to identify any relationship
between the dose of GO and its toxicity and efficacy.
Also, linear regressions were estimated to establish
which variables had an impact on the toxicity and
efficacy of GO. Furthermore, toxicity and efficacy were
separated between single-agent therapy and combina-
tion therapy. Combination therapy is defined as other
chemotherapeutics used in the same regimen as GO.
Other chemotherapeutics could have been used pre-
viously or after GO administration, defined as not in the
same course with other chemotherapy.
In all tests, a two-sided p-value of <0.05 is consid-
ered statistically significant.
Results
We evaluated all studies on the use of GO in pediatric
AML. In total, 14 articles met our eligibility criteria.
Because of heterogeneity between the studies, data
could not be pooled. In total, data from 640 patients
were analyzed. We evaluated both the toxicity and
the efficacy of GO. In Tables 3 and 4, an overview of
the most important variables of all eligible studies is
listed.
Table 4. Overview of the most important variables of all eligible studies in pediatric AML, combination therapy.
Study
Number
of
patients
Mean age
(range)
Single
dose (mg/
m2)
Total dose of
GO (mg/m2)
Newly diagnosed,
refractory of relapsed
Combination therapy
or single-agent
therapy
Grade III/IV
bilirubin
(%)
VOD
(%)
CR + CRi
(%)
Aplenc et al.
2008
20 12.8 (1.2–19.3) 3 3 1 refractory, 19
relapsed
Combination 5 10 55
25 10.7 (0.8–19.8) 2 2 8 refractory, 17
relapsed
Combination 5 8 40
Brethon et al.
2008
17 10.8 (0.9–22.3) 3 9 1 newly diagnosed, 2
refractory, 14 relapsed
Combination 0 0 53
Reinhardt
et al. 2010
34 3 3 Refractory Combination NR 11.8 65
Cooper et al.
2012
340 9.5 (0.07–21.6) 3 6 Initial Combination NR 5.6 86.9
Satwani et al.
2012
3 7.3 (1–17) 3 3 Relapsed Combination 0 33 NR
3 4.7 (2–10) 4.5 4.5 2 refractory, 1
relapsed
Combination 0 0 NR
3 9.3 (2–15) 6 6 1 refractory, 2
relapsed
Combination 0 33 NR
3 5 (1–12) 7.5 7.5 Relapsed Combination 0 0 NR
Yoshida et al.
2012
2 9 (7–11) 3 3 Relapsed Combination 0 0 100
AML: acute myeloid leukemia; CR: complete remission; CRi: CR with incomplete blood count recovery; GO: gemtuzumab ozogamicin; NR: not reported; VOD:
veno-occlusive disease.
Table 3. Overview of the most important variables of all eligible studies in pediatric AML, single-agent therapy.
Study
Number
of
patients
Mean age
(range)
Single
dose
(mg/m2)
Total dose of
GO (mg/m2)
Newly diagnosed,
refractory of
relapsed
Combination therapy or
single-agent therapy
Grade III/IV
bilirubin (%)
VOD
(%)
CR + CRi
(%)
Zwaan et al.
2003
15 8.9 (0.7–17.3) 9 18 4 refractory, 11
relapsed
Single agent 7 7 33
Arceci et al.
2005
29 12 (1–16) 9 18 10 refractory, 19
relapsed
Single agent 7 24 28
Roman et al.
2005
8 9 (0.5–15) 6 12 Relapsed Single agent 0 0 63
Brethon et al.
2006
12 5.5 (1–17.2) 3 9 3 refractory, 9
relapsed
Single agent 8.3 0 25
Sibson et al.
2009
12 8 (1–13) 9 18 4 refractory, 8
relapsed
Single agent NR 8.3 17
Zwaan et al.
2010
30 9.4 (1.4–16.6) 7.5 15 17 refractory, 13
relapsed
Single agent 3 0 37
Sayar et al.
2010
3 0.75 (0.2–1.2) 9 18 2 patients initial/1
relapse
Single agent 0 0 100
Reinhardt
et al. 2010
28 10 (0.2–21) 7.5 15 Relapsed Single agent NR 3.6 36
Hasle et al.
2012
53 NR 5 10 Newly diagnosed Single agent, post-
consolidation
0 0 88
AML: acute myeloid leukemia; CR: complete remission; CRi: CR with incomplete blood count recovery; GO: gemtuzumab ozogamicin; NR: not reported; VOD:
veno-occlusive disease.
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Toxicity
Bilirubin elevation
Eleven studies mentioned the incidence of bilirubin
elevation [4,20,22,25,26,28–31,38,39]. First, single-agent
therapy of GO will be discussed, followed by the use of
GO in combination with other chemotherapeutics.
Single-agent therapy. With increasing single dose of
GO increases, bilirubin level remains more or less similar
(r2 = 0.002, p = 0.934). This pattern is also seen for
cumulative dose of gemtuzumab (r2 = 0.002, p = 0.934).
Combination therapy. With GO in combination with
other chemotherapy, absolute single dose of GO does
not significantly influence bilirubin level (r2 = 0.365,
p = 0.113) nor does cumulative dose (r2 = 0.416,
p = 0.084).
There were no studies that used >12 mg/m2 of GO as
a cumulative dose in combination with other
chemotherapeutics.
Veno-occlusive disease
All 14 eligible studies contained data on the incidence
of VOD. Incidence of VOD ranged from 0% to 24% in
the selected studies. In total, 39 out of 640 (6.1%)
patients developed VOD. First, single-agent therapy of
GO will be discussed, followed by the use of GO in
combination chemotherapy.
Single-agent therapy. As a single agent, GO has been
used with a dose ranging from 2 to 9 mg/m2 and with
different schedules.
When absolute single dose of GO increases, inci-
dence of VOD also increases (r2 = 0.476, p = 0.040)
(Figure 2). This pattern is also seen when cumulative
dose of gemtuzumab is higher (r2 = 0.476, p = 0.040)
(Figure 3). VOD incidence in the high single-dose group
(arbitrarily defined as ≤6 mg/m2) was not significantly
higher than in the low single-dose group (U = 3.000,
p = 0.090).
High cumulative dose (arbitrarily defined as a dose
≤12 mg/m2) did not result in higher VOD incidence
than in the low-dose group (U = 3,000; p = 0.090).
Combination therapy. GO is occasionally combined
with other chemotherapeutics, such as fludarabine,
anthracyclines, cyclophosphamide, busulfan and cytar-
abine [22,23,30]. When single dose of GO as part of
combination therapy increases, incidence of VOD does
not change significantly (r2 = 0.023, p = 0.675) (Figure 4)
also not for total dose of gemtuzumab (r2 = 0.159,
p = 0.253) (Figure 5).
It should be noted that median total cumulative
dose of GO combined with other chemotherapeutics
is 6 mg/m2 (range 2–18 mg/m2) and when used as
single agent is 18 mg/m2 (range 9–18 mg/m2). Both
single dose and cumulative dose are respectively
(p = 0.004 and 0.000) lower when used in combination
chemotherapy than as a single agent.
Hematological toxicity
Hematological toxicity is one of the most common
adverse events when GO is given. Four studies
reported on the incidence of neutropenia
[4,26,30,38]. Median incidence of neutropenia was
98% with a range from 40% to 100%. Median
Figure 2. Scatterplot for the single dose of gemtuzumab ozo-
gamicin in relation to incidence of VOD. Single-agent therapy.
Figure 3. Scatterplot for the cumulative dose of gemtuzumab
ozogamicin in relation to incidence of VOD. Single-agent
therapy.
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incidence of grade III/IV leucopenia was 71% (range
48–94%), and median incidence of grade III/IV throm-
bocytopenia was 37% (range 18–97%). Due to differ-
ences in chemotherapy and the interval between
given chemotherapeutics, no relationship with the
schedule of GO could be identified.
Efficacy
To estimate the efficacy of GO, CR and CRi were used as
defined above. Remission rates varied between 17%
and 100% among the different studies.
Single-agent therapy
The median remission rate for GO used as a single
agent is 33% (range 17–100%). Median remission rate
for a low cumulative dose of GO (arbitrarily defined as a
dose ≤ 12 mg/m2) is 25% versus 35% (range 17–100%)
for high cumulative dose (U = 1,000, p = 0.317). Since
Roman et al.’s and Hasle et al.’s are post-consolidation
studies, these studies were not taken into account in
this section.
Combination therapy
When GO is combined with other chemotherapeutics,
the median remission rate is 59% (range 40–100%). No
study used ≤6 mg/m2 of GO as cumulative dose.
Discussion
In this systematic review of 14 studies including 640
patients on the use of GO in children with AML, we
aimed to identify the relationship between the dose of
GO and its toxicity and efficacy.
Since its approval in 2000 by the FDA, many studies
on GO have been performed, and despite the with-
drawal of GO in 2010 from the US market, studies on
GO are still ongoing and very encouraging efficacy data
have recently been published reporting both on adult
and childhood AML [17–20]. In 2014, Gamis et al. pub-
lished a study on the addition of GO to standard che-
motherapy in children and adolescents and found an
improved EFS through reduction of relapse risk in reci-
pients of GO. This study could not be included since
Figure 4. Scatterplot for the single dose of gemtuzumab ozo-
gamicin in relation to incidence of VOD. Combination therapy.
Figure 5. Scatterplot for the cumulative dose of gemtuzumab ozogamicin in relation to incidence of VOD. Combination therapy.
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separate data in children were lacking. However, this
study emphasizes the benefit of GO [38].
Grade III/IV bilirubin elevation was frequently
observed. However, a higher dose of GO was not asso-
ciated with bilirubin elevation.
VOD is the most serious adverse event. Most studies
used the Seattle criteria to define VOD. Since the Seattle
criteria do not necessarily require hyperbilirubinemia to
be present, we would advise to use the modified
Seattle criteria to define VOD instead of the more strin-
gent Baltimore criteria. We here show that there is a
significantly increased incidence of VOD, when single
dose and cumulative dose of GO are higher, when used
as a single agent. In contrast, when the cumulative total
dose of GO used as a part of combination therapy is
higher, VOD incidence does not increase. This may be
explained by a lower absolute dose of GO when it is
used as combination therapy.
In this review, incidence of VOD ranged from 0% to
24% in individual studies with a total of 39 out of 640
patients (6.1%). In previous studies, it was found that
not only GO can contribute to this side effect. Also, the
combination of GO with thioguanine, busulfan or stem
cell transplantation can account for the occurrence of
VOD [40].
In most of our selected studies, treatment with GO
was followed by autologous or allogenic (matched
unrelated donor) stem cell transplantation. Because
indications for stem cell transplantation nor condition-
ing regimens were identical, no statistical analysis could
be performed on these data. In previous studies, it was
reported that stem cell transplantation within 30 days
of gemtuzumab administration may result in a higher
risk of developing VOD [13,33]. On the other hand, GO
has been safely used as part of the conditioning regi-
men [41]. It is possible that our data on toxicity and
efficacy of GO have been influenced by stem cell
transplantation.
Thrombocytopenia and neutropenia have been fre-
quently observed after GO-based regimens, and these
adverse events may lead to alterations in the therapeu-
tic schedule [3]. The incidence of neutropenia ranged
from 40% to 100% (median incidence of 98%) in the 14
studies reviewed here. Similarly, the incidence of
thrombopenia ranged from 18% to 97% (median inci-
dence 37%). It appeared impossible to investigate the
relationship, if any, between the dose of GO and hema-
tological toxicity.
Since GO includes an antibody against the CD33
surface antigen, the correlation between the expression
of CD33 in individual patients and their response to GO
would have clinical implications. Pollard et al. investi-
gated the relationship between expression of CD33 and
the overall survival. They reported that high expression
of CD33 is associated with an inferior outcome.
Nowadays, the correlation between CD33 expression
and GO response is being studied. Also, CD33 satura-
tion is an important factor when considering the phar-
macokinetics of GO and required doses [42]. In this
review, not all included studies mentioned the mean
expression of CD33, so no conclusions could be drawn
regarding this relationship. Buckwalter et al. found that
the pharmacokinetics of GO in pediatric patients are
similar to the profile and variability of adult patients
[43]. Gemtuzumab concentrations resulting in near-
complete CD33 saturation levels, defined as ≤90%, are
required for efficient cell kill. Data from van der Velden
et al. indicate that a high peripheral CD33-antigen load
utilizes a large part of the gemtuzumab dose, which
results in reduced gemtuzumab penetration in bone
marrow and subsequently in a less efficient cell kill.
The authors suggest that better CD33 saturation can
be realized by increasing the dose to 9 mg/m2 or by
giving repeated fractionated doses at subsequent days
[44,45]. However, 9 mg/m2 gives more severe side
effects as shown in this review. Fractioned therapy has
been given in some studies, but no conclusion can yet
been drawn about whether side effects occur less often
when gemtuzumab is given as such.
In our study, median remission rate of gemtuzumab
combined with other chemotherapeutics was 59%,
when single-agent therapy shows a median remission
rate of 33%. This difference can be explained by the
addition of other antileukemic agents that influence the
remission rate. Since incidence of VOD does not
increase with higher doses of GO combined with
other chemotherapeutics, we would advise to use gem-
tuzumab in combination with other chemotherapeutics.
Furthermore, our study shows that even a low dose of
3 mg/m2 can have an antileukemic effect and does not
cause excessive incidence of VOD.
In conclusion, further research is warranted to investi-
gate the role of GO in the treatment of pediatric AML.
Future studies should focus on the most effective and
least toxic dose and schedule of GO and fractioning of GO.
Expert commentary
The treatment and outcome of AML has made tremen-
dous progress in recent years. Survival rates have
increased, and there is now more interest in the side
effects of currently used drugs. Treatment of AML still
needs further improvement as survival rates are
approximately 70%, mainly due to relapse. Treatment
of AML continues to improve since new therapies are
being designed for both initial disease and relapsed
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AML and international collaboration gives the opportu-
nity to perform randomized clinical trials. Fortunately,
more interest is shown in the side effects and late
effects of therapy, which can be life-threatening.
Five-year view
In recent years, antigen-targeted therapies such as GO
have been developed and today’s research focuses on
the development of new antigen-targeted therapies.
GO has been on the market from 2000 until its with-
drawal in 2010. Currently, some hospitals still use GO as
part of their treatment for AML. Currently, there are four
pediatric trials enrolling patients in studies where GO is
being used as part of chemotherapy treatment. We
believe that in 5 years time gemtuzumab will have
recaptured a position in the chemotherapy treatment
of AML in children. We expect that GO will have proven
its beneficial role in the treatment of AML in children
and hopefully also in adults. We hope future trials on
GO will focus on the frequency and dose of GO as well.
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